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Abstract Cranial or cervical vascular disease is commonly
associated with headaches. The descriptions may range from
a thunderclap onset of a subarachnoid hemorrhage to a
phenotype similar to tension type headache. Occasionally,
this may be the sole manifestation of a potentially serious
underlying disorder like vasculitis. A high index of clinical
suspicion is necessary to diagnose the disorder. Prompt
recognition and treatment is usually needed for many con-
ditions to avoid permanent sequelae that result in disability.
Treatments for many conditions remain challenging and are
frequently controversial due to paucity of well controlled stud-
ies. This is a review of the recent advances that have been made
in the diagnosis or management of these secondary headaches.
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Introduction
In the early part of twentieth century, studies on man and
lower animals demonstrated that the cranial blood vessels
are pain-sensitive structures, capable under special circum-
stances of giving rise to headache. It was enticing to believe
that the distention of certain branches of the external carotid
arteries was chiefly responsible for migraine headache and
the headache associated with arterial hypertension [1].
Our understanding of causation of headaches including
migraine has continued to evolve with overall advances in
neuroscience. An emerging concept over the last year has
been to view primary headaches as a dysfunction of the
neurolimbic network (Table 1) [3], with evidence to suggest
that vascular change is neither necessary nor sufficient for
migraine [4]. However, this has not challenged the close
association of headaches with vascular disease of the head
and neck region. The ICHD aptly recognizes that head-
ache related to vascular disease is a secondary headache
that may differ from, or mimic the phenomenology of
the primary headaches [2].
In a recent report Galletti et al. [5] found that large
majority of patients with arteriovenous malformation, in
which headache was the main symptom at presentation,
attacks mirrored the clinical features of migraine by
ICHD-II criteria. This was most correlated with an occipital
lobe location of the AVM.
The International Classification of Headache Disor-
ders further defines a diagnosis of “headache attributed
to vascular disorder” as definite only when the headache
resolves or greatly improves within a specified time
after its onset or after the acute phase of the disorder.
When this is not the case, or before the specified time
has elapsed, the diagnosis is qualified by stating “prob-
ably attributed to vascular disorder”. Recognizing that
these are criteria which cannot be applied in all in-
stances, especially when the headache does not resolve
or greatly improves after 3 months, leads to a diagnosis
of chronic post–vascular-disorder headache. This time
based criteria are arbitrary and controversial.
There are many features of headaches that suggest a second-
ary headache. The mnemonic 2SNOOP4 secondary headaches,
has been utilized for many years as an aid to remember the red
flags that should prompt a search for an underlying cause [6•].
& Systemic symptoms (fever, weight loss, fatigue)
& Secondary risk factors (HIV, cancer, immunodeficiency)
& N Neurologic symptoms/signs (altered mental status,
focal deficits)
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& Onset/ (split-second, thunderclap)
& Older (new after age 50)
& P: prior history/ positional / papilledema / precipitants
Besides the well-recognized red flags, there are other
“yellow flags” that should alert the examiner and includes
a headache that wakes patient from sleep at night or new-
onset side-locked headaches [7••]
Thunderclap Headache
Thunderclap headache or a headache that is abrupt or
hyperacute in onset is probably the most common pheno-
type of a headache widely recognized to be associated with
a vascular cause. The diagnosis of headache and its causality
is easily established when focal neurological deficits accom-
pany the vascular disease and its consequences like hemor-
rhage (Table 2). This is probably most obvious in case of a
ruptured aneurysm resulting in a subarachnoid hemorrhage
associated with a classic thunderclap headache. When hem-
orrhage is not obvious on imaging, CSF analysis may be
necessary to evaluate for subtle hemorrhage. When hemor-
rhage has been reasonably excluded, other etiologies need to
be considered and should include cervical artery dissection,
cerebral venous sinus thrombosis, pituitary apoplexy and
reversible cerebral vasoconstriction syndrome, vasculitis
besides others. While vascular headaches can rarely mimic
primary headaches, non-vascular causes like spontaneous
CSF leaks can also result in thunderclap onset headache
[8] with subtle imaging findings that are easily missed. A
diligent search for secondary causes is also warranted with
all persistent headaches. However the presentation may not
be that obvious in conditions that are more gradual in onset.
On many occasions vascular disease develops in individuals
with pre-existing primary headaches and the only clue is a
change of the headache type. A high index of suspicion is
especially needed in the elderly who are at risk for devel-
oping arteritis with its disabling consequences.
Headache Attributed to Unruptured Vascular
Malformation
Headache is occasionally an indirect consequence of the
vascular disease such as a result of an infarct or hemorrhage
consequent to the vascular pathology. However, headache
can occur in the presence of an uncomplicated vascular
pathology. This becomes especially challenging when the
headache resembles a primary headache disorder like mi-
graine or cluster and does not adhere to the strict ICHD-II
definitions of a vascular headache [9]. Previously, occur-
rence of a primary headache phenotype in a patient with a
vascular malformation has been considered to be an inci-
dental finding, but response of the headache, to treatment of
the underlying vascular malformation, raises an argument
against that notion. Patients with complaints of headaches
who are found to have an unruptured aneurysm often pre-
sume a direct relationship. In a very eloquent prospective
study, Schwedt and colleagues demonstrated approximately
2/3 of patients with pretreatment headaches had substantial
reductions in headache frequency following treatment of
unruptured aneurysm [10••]. This was consistent with pre-
vious retrospective studies by Qureshi [11•] and Kong [12•].
As discussed by all authors, reduction of headache was in
part attributed to reduction of anxiety, consequent to reduc-
tion of risk of rupture. Another recent prospective study by
Choxi et al. arrived at similar conclusions [13]. They con-
cluded that 92.45 % (n=53) of patients who filled both a
preoperative and postoperative pain score had a statistically
Table 1 Types of headaches attributed to cranial or cervical vascular
disorders
1. Headache attributed to ischemic stroke or transient ischemic attack
2. Headache attributed to nontraumatic intracranial hemorrhage
3. Headache attributed to unruptured vascular malformation
4. Headache attributed to arteritis
5. Carotid or vertebral artery pain
6. Headache attributed to cerebral venous thrombosis
7. Headache attributed to other intracranial vascular disorder
(After ICHD-II)
For all vascular headaches, the diagnostic criteria include whenever
possible: [2]
A. Headache with one (or more) of the stated characteristics (if any
are known) and fulfilling criteria C and D
B. Major diagnostic criteria of the vascular disorder
C. The temporal relationship of the association with, and/or other
evidence of causation by, the vascular disorder
D. Improvement or disappearance of headache within a defined
period1 after its onset or after the vascular disorder has remitted or
after its acute phase
Table 2 Considerations with thunderclap headache
• Subarachnoid hemorrhage
• Arteriovenous malformations
• Reversible cerebral vasoconstriction syndrome
• Dissection
• Vasculitis
• Cerebral venous thrombosis
• Spontaneous intracranial hypotension
• Pituitary apoplexy
• Primary thunderclap headache
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significant improvement in their headache score over an
average period of 32 months. There was no relationship
found between headache characteristics and aneurysm size,
laterality of aneurysm or method of treatment, i.e., surgical vs.
endovascular treatment. It is to be noted that this study had
significant limitations, including selecting only patients that
had experienced headache prior to the procedure, were treated
by a single surgeon, and who filled out questionnaires subse-
quent to the procedure. Emotional well-being or anxiety was
not taken into account. A similar but less robust response was
seen in the elderly population treated with an endovascular
approach utilizing coils alone, balloon-remodeling technique,
and stent-assisted coiling [14].
These and other studies have also remarked upon a small
subset of patients who experienced worsening of their head-
aches in the absence of a complication. This group was the
subject of a retrospective study by Baron et al. [15] looking
at the development of headache following a variety of
endovascular procedures. They also found an initial reduc-
tion of headaches following treatment of the vascular mal-
formation. However when patients were followed over a
longer term, there was a return of the pre-existing headache.
This was usually beyond the limits noted in the ICHD-II
criteria (develops within seconds of the procedure and re-
solves within 24 hours) [2]. Postprocedural headache
followed intracranial coiling, acrylic glue embolization,
and stenting in order of decreasing probability. Head-
ache after the procedure was higher in women, with
comorbid smoking and/or anxiety/depression. The same
study also found that further diagnostic testing was low
yield. In addition, triptans and dihydroergotamine were
used without incident in a small group of pre- and
postcoil patients. This suggested that for migraineurs
with aneurysm, there may not be an absolute contrain-
dication to these medications. Caution is still warranted,
as the numbers were very small to infer overall safety.
Another study that raised caution against the newer
generation of coils concluded that endovascular emboli-
zation of unruptured intracranial aneurysms using bioac-
tive coils, resulted in a higher onset rate of mild
headaches and greater temperature elevation after treat-
ment than did use of bare platinum coils due to the
inflammatory effect of the polyglycolic acid [16].
In summary, it appears that the headache responds to
amelioration of anxiety relating to the knowledge of an aneu-
rysm rather than the pathology itself. When anxiety persists
after the procedure, so does the headache over the long term.
Headache Attributed to Arteritis
Headache is the most common symptom with CNS vascu-
litis. These can either be secondary to CNS involvement in
systemic vasculitides or be associated with the rare primary
CNS vasculitis. The headache can be generalized or local-
ized, is gradually progressive with periods of remission.
This is in contrast to the headache associated with reversible
cerebral vasoconstriction syndrome where onset is typically
acute with thunderclap headache—extreme head pain
peaking in less than 1 min, mimicking that of a ruptured
aneurysm. Screaming, crying, agitation, confusion, and col-
lapse are common because of the excruciating pain. Typical
headache is bilateral (although it can be unilateral), with
posterior onset followed by diffuse pain. Nausea, vomiting,
photophobia, and phonophobia in frequently occur [17••].
A symptom that should elicit a careful search for an under-
lying condition may be stabbing headache. Rampello et al.
reported their findings in 26 patients recruited over 10 years,
with stabbing headache. More than half of these patients had
autoimmune disorders, including multiple sclerosis, Sjogren's
disease, systemic lupus erythematosus, Behcet's disease, au-
toimmune vasculitis, and antiphospholipid antibody syn-
drome. They speculate that stabbing headache may develop
as a result of neuroinflammation and, at least in some cases,
may be an epiphenomenon of focal demyelinating lesions of
the upper or lower brain stem [18].
A long established cause of secondary vascular headache
is Giant Cell arteritis (GCA), which is one of the commonest
vasculitides. It is closely associated with polymyalgia
rheumatica that also targets the same group of patients,
frequently occurring together in the same individual, char-
acterized by focal or diffuse myalgia associated with weak-
ness and weight loss. Diagnosis is suspected when there is
new onset temporal headache associated with scalp tender-
ness. Jaw and tongue claudication may be associated and it
is frequently accompanied by visual symptoms (diplopia, or
visual loss). This disabling complication may be permanent
and hence a high index of suspicion needs to be maintained
when encountering patients with a new or change of head-
ache. American College of Rheumatology diagnostic
criteria include the following; age of onset greater than
50 years; onset of new headache ; temporal artery abnor-
mality (tender or reduced pulsation) ; elevated erythrocyte
sedimentation rate, >50 mm/h using the Westergren method;
abnormal arterial biopsy—showing necrotizing vasculitis
with predominant mononuclear cell infiltration or granulo-
matous inflammation [19••]. Biopsy remains the test of
choice to establish the diagnosis but given the risk of com-
plications, prompt treatment should ensue. Initial treatment
is with corticosteroids. Use of high-dose intravenous ste-
roids as initial therapy is preferred by many, especially when
visual complaints are present but this remains highly con-
troversial [20]. The last decade has witnessed a much im-
proved understanding of the immunopathology of GCA,
and is impacting the diagnostic approach to patients with
GCA. Immunologic studies suggest a much more chronic
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course of the disease than previously appreciated. Accord-
ingly, current therapeutic strategies, while successful in
managing acute disease, need to be adapted to longer term
goals. An overriding challenge is the advanced age of the
affected patient population. While immune aging emerges
as one of the underlying pathogenic principles in conferring
risk for GCA, it also restricts the potential use of more
aggressive means to immunosuppress vessel-wall centered
chronic inflammation. Other treatment options include the
use of methotrexate, azathioprine, cyclosporine [19••], cy-
clophosphamide [21], atlizumab [22, 23•] among other im-
mune modulating therapy. Atlizumab is a humanized
monoclonal antibody against the interleukin-6 receptor
(IL-6R) interfering with cytokine function. Although GCA
is the commonest systemic vasculitis, prospective random-
ized trials on steroid sparing agents are rare and mostly
included only small patient numbers. There is an urgent need
for prospective randomized trials with larger patient groups,
longer follow-up, and well defined inclusion criteria and
criteria for response and relapse, using standardized disease
activity scoring systems, in order to be able to give evidence-
based recommendations for patients not responding to gluco-
corticoids alone in the future [24].
Takayasu arteritis (TAK), a disease very similar to GCA,
is a rare disorder typically recognized in younger individuals
of Asian origin and female gender. This is, however, con-
troversial and studies show that the disease is distributed all
over the world and is not restricted to any one ethnic group
[25]. Symptoms, signs, and imaging abnormalities that are
characteristic of GCA or TAK are often present, albeit in
differing frequencies, in both disorders and this may repre-
sent skewed phenotypes within the spectrum of a single
disorder [26]. In a recent description of this illness in chil-
dren, the median time lag between the first onset of symp-
toms and diagnosis was 7.7 weeks. Hypertension was the
most common finding on first presentation (93 %), followed
by headache (64 %), nausea (64 %) and palpitation (50 %).
Ten patients (71 %) had reduced or absent carotid, brachial
or femoral pulses in one or more locations. C-reactive pro-
tein was elevated in 79 % of the patients and erythrocyte
sedimentation rate in 64 %. Vascular imaging showed ex-
tensive vasculitis of most major arteries in the body in 86 %
of patients. Conservative drug treatment was effective in
50 %. Interventional dilatation of stenosis and surgical ther-
apy, including aortic bypass, resection of aneurysms and
nephrectomy, were necessary in the remaining patients
[27]. Anti-inflammatory therapy can lead to dramatic im-
provement in TA. The 5-year survival rate in adults is as
high as 94 %. Preventing organ damage is critical in insur-
ing a favorable prognosis [25].
Behcet's syndrome (BS) is a chronic relapsing vascular
inflammatory disease of unknown etiology with high mor-
bidity and mortality. In a study of clinical patterns of CNS
disease in a group of patients with BS, headache was the
most common symptom (86.6 % of cases), pyramidal affec-
tion (signs of upper motor neuron lesions/hemiplegia) was
reported in 33.3 %, attacks of disturbed conscious level in
26.6 %, and cranial nerve affection in 6.5 %. Of the patients,
66.6 % with clinical features of neuro-Behcet (NBS) had
statistically significant radiographic evidences of cerebro-
vascular disease. Patients with NBS had significantly higher
disease activity index score. Radiographic findings and flow
abnormalities were significantly less in patients on immune
suppressants and antiplatelet drugs. BS patients with clinical
neurologic disease were found to have radiographic findings
suggestive of cerebral vascular disease with high disease
activity index score. Drugs like immunosuppressants and
oral antiplatelets might retard cerebral vascular disease pro-
gression and flow abnormalities, respectively [28]. Migraine
without aura did prove to be the most frequent type of
headache in BS patients (with and without neurological
involvement) and there were no differences in the frequency
of the different pattern of headache between BS patients and
controls [29].
Primary angiitis of the CNS also needs to be considered
in the differential though its occurrence is being challenged.
Many of the patients previously diagnosed as such, may
have RCVS [30]. Other differentials not discussed in detail
include polyarteritis nodosa, Kawasaki disease, Wegener's
granulomatosis, systemic lupus erythematosus, and
vasculitits secondary to infections.
Carotid or Vertebral Artery Pain
Head and neck pain as a consequence of cervical artery
dissection (carotid and vertebral) has been recognized for
many decades. The location of the pain is variable and can
involve, in isolation or in combination, any part of the head,
face and neck, usually ipsilateral to the pathology; however,
bilateral and diffuse headache can occur, even when the
dissection is unilateral. The pain can sometimes be very
localized with a predilection for the frontal, orbital, temporal
and upper cervical regions. It can also simulate migraine,
cluster headache or carotidynia [31]. Horner’s syndrome;
cranial-nerve palsy; tinnitus; and, rarely, cervical-root injury
are the most common associated symptoms that attract at-
tention to the secondary nature of the pain [32••]. It has also
been shown that the risk for cervical artery dissection
(CAD) is doubled for any migraine [33]. It has hence been
postulated that CAD may explain the increased risk of
ischemic strokes associated with migraines. The group par-
ticipating with CADISP (Cervical Artery Dissection and
Ischemic Stroke Patients, a multinational European net-
work) [34] also found both migraine with and without aura
to be more frequent in patients with cervical artery
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dissection, as compared to healthy controls and stroke pa-
tients without a dissection. Within patients with a dissection,
presence or absence of migraine did not impact the preva-
lence of strokes, arterial distribution, or other clinical or
prognostic features [35••]. In a separate study in the same
cohort of patients, the authors found that patients with
carotid artery dissection were older, more often men, more
frequently had a recent infection (odds ratio of 1.59), and
tended to report less often a minor neck trauma in the
previous month (OR=0.75 [0.56–1.007]) compared to pa-
tients with vertebral artery dissection. Clinically, patients
with internal carotid artery dissection more often presented
with headache at admission but less frequently complained
of cervical pain or had cerebral ischemia than patients with
vertebral artery disease. It was also noted that multiple
concomitant dissections tended to cluster on the same artery
type rather than involving both a vertebral and carotid artery
[36]. An important cause of dissection is fibromuscular
dysplasia, which is a nonatherosclerotic, noninflammatory
vascular disease that primarily affects women in the prime
of their life. It commonly involves the renal, carotid, and
vertebral arteries. In one of the largest cohort of
fibromuscular dysplasia patients [37], the most common
clinical manifestations noted were hypertension, headaches,
pulsatile tinnitus, and dizziness, but dissection, aneurysm,
transient ischemic attack, and stroke also occur with a high
frequency. Headaches were a common symptom (60.0 % of
patients), with classical migraine-type headaches reported in
32.2 %. Severe headaches occurred weekly in 13.1 % of
patients and daily in 12.5 % of patients. Since the affected
population, also has one of the highest prevalence for mi-
graine, a high index of suspicion needs to be maintained.
Once the pathology is clinically suspected, prompt con-
firmation of the diagnosis and commencing treatment for the
underlying condition is warranted. There is class I evidence
that contrast-enhanced CT angiogram, MR angiogram and
catheter-based contrast angiography are all useful for diag-
nosis of cervical artery dissection (level of evidence: C)
[38••]. Regarding treatment , there is class IIa evidence that
for patients with symptomatic cervical artery dissection,
anticoagulation with intravenous heparin (dose adjusted to
prolong the partial thromboplastin time to 1.5 to 2.0 times
the control value) or low-molecular weight heparin (in ap-
propriate dose) followed by warfarin [dose adjusted to
achieve a target INR of 2.5 (range 2.0 to 3.0)], or oral
anticoagulation without antecedent heparin, can be benefi-
cial for 3 to 6 months, followed by antiplatelet therapy with
aspirin (81–325 mg daily) or clopidogrel (75 mg daily, level
of evidence: C) [38••].
In addition, there is class IIb evidence supporting the
consideration of carotid angioplasty and stenting when is-
chemic neurological symptoms have not responded to
antithrombotic therapy after acute carotid dissection (level
of evidence: C) [38••]. The safety and effectiveness of
pharmacological therapy with a b-adrenergic antagonist,
angiotensin inhibitor or non-dihydropyridine calcium chan-
nel antagonist (verapamil or diltiazem) to lower blood pres-
sure to the normal range and reduce arterial wall stress are
not well established (level of evidence: C)
Independent of dissections, occurrence of headaches has
been described with performance of cerebral and carotid
angiogram, endovascular and surgical manipulation of the
carotid and vertebral vessels.
Intracarotid or intravertebral injection of contrast induces
a diffuse severe headache with a burning sensation which
resolves spontaneously. The injection can also trigger a
migraine attack in a person who has migraine. A very
specific subtype of headache has been reported after balloon
inflation or embolization of an AVM or aneurysm. It is a
severe pain of abrupt onset, localized in specific areas
according to the artery involved, occurring within a few
seconds of the procedure and disappearing rapidly [2]. In a
recent study, frequency of headache after internal carotid
stenting was 39.1 % as compared to 21.9 % angiography
alone. The headache commonly arose in a short period after
the procedure and was relieved in 10 minutes. In both cases
headache was mild, ipsilateral, frontotemporal in location,
pressing in nature, and arose frequently and resolved within
10 minutes after the procedure. Both types of headache were
related to severe stenosis, however described as pressing
after carotid stenting and burning after angiography [39].
Headache Attributed to Cerebral Venous Thrombosis
Cerebral venous thrombosis (CVT) is a rare type of cere-
brovascular disease that can occur at any age, including in
neonates, and it accounts for 0.5 % of all strokes. CVT is
more common than previously thought and it is recognized
as a nonseptic disorder with a wide spectrum of clinical
presentations, numerous causes, and usually a favorable
outcome with a low mortality rate [40]. Isolated headache
as the sole presenting manifestation of CVT has also been
described [41] with variable estimates of its occurrence [42].
When present the most frequent characteristics were: recent
onset rapidly progressive severe headache with a persistent
course; unilateral location and throbbing quality. Rarely, the
headache may mimic migraine or cluster headache [41]. In
another series of patients, the quality of headache was
reported as throbbing, band like, thunderclap, and other
(pounding, exploding, stabbing). The location of headache
was reported as unilateral, localized or diffuse by an equal
number of patients [43]. The spectrum of clinical symptoms
reflects the degree of venous congestion, which depends not
only on the extent of thrombosis in the deep veins but also
on the territory of the involved vessels and the establishment
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of venous collaterals [44]. Oral contraceptive intake, preg-
nancy, and the puerperium are responsible for the vast
majority of CVT occurring in young women, usually in
association with other prothrombotic risk factors, particular-
ly congenital thrombophilia [45]. Some cases have been
described recently where CVT is emerging as a complica-
tion of spontaneous intracranial hypotension [46–48] MRI
with combined with magnetic resonance angiography are
the best diagnostic methods. D-dimer concentrations are
raised in most patients but normal D-dimers do not rule
out CVT, particularly in patients who present with isolated
headache [40]. Heparin is the first-line treatment, but in a
few cases more aggressive treatments, such as local intrave-
nous thrombolysis, mechanical thrombectomy, and
decompressive hemicraniectomy, may be required [40••].
There is no contra-indication for further pregnancies when
this occurs in relationship to pregnancy, but a permanent
contra-indication for all estrogen-based contraception [45].
Headache Attributed to Other Intracranial
Vascular Disorder
Reversible cerebral vasoconstriction syndrome (RCVS) is
characterized by the association of severe headaches with or
without additional neurological symptoms and a ‘string and
beads’ appearance on cerebral arteries, which resolves spon-
taneously in1 to 3 months. RCVS is spontaneous in a third
of the patients and secondary in the other two-thirds. The
main pattern of presentation (94 % of patients) was multiple
thunderclap headaches recurring over a mean period of
1 week. Various complications were observed, with different
time courses. Cortical subarachnoid hemorrhage (cSAH),
intracerebral hemorrhage, seizures and reversible poste-
rior leukoencephalopathy were early complications, oc-
curring mainly within the first week. Ischemic events
occurred significantly later than hemorrhagic events.
The different time courses of thunderclap headaches,
vasoconstriction and strokes suggest that the responsible
vasospastic disorder starts distally and progresses to-
wards medium sized and large arteries [49••]. RCVS
and primary angiitis of the central nervous system
(PACNS) can affect both the medium and the small
vessels. The diagnosis of small-vessel cerebral
arteriopathies requires a high level of clinical suspicion,
astute interpretation of imaging findings, and a detailed
examination of the skin, eye, or other organ systems
[50]. RCVS has about a ten percent overlap with pos-
terior reversible encephalopathy syndrome(PRES) [51•],
with many shared associations and etiologies and a
hypothesis of shared pathophysiology. It has been hypoth-
esized that either the episodes of systemic hypertension lead to
hyperperfusion, or cerebral vasoconstriction and therefore
hypoperfusion result in vasogenic edema observed in PRES
[52]. Mainstay of treatment remains calcium-channel blockers
including intravenous nimodipine [49••], intravenous prosta-
cyclin [53] and intra-arterial delivery of milrinone [54],
nimodipine [55], verapamil [56] that have been reported to
be beneficial.
Occurrence of headaches is a well-known manifestation
of cerebral autosomal dominant arteriopathy with subcorti-
cal infarcts and leukoencephalopathy (CADASIL) which is
a result of mutation of the NOTCH3 gene. This leads to
deposition of the NOTCH3 cleavage product in the vascular
smooth-muscle cells both in cerebral and extracerebral ves-
sels [57]. Sathe and colleagues recently describe their
experience in twenty confirmed cases. Recurrent acute
confusional episodes associated with migraine in adults
appeared to be a phenomenon unique to CADASIL [58]
Prolonged aura and atypical aura has also been de-
scribed previously [59] as a concerning feature of mi-
graines, when associated with white matter disease on
imaging, should prompt further genetic testing. Head-
aches associated with unexplained combination of neu-
rological and non-neurological disease in a patient or
kindred, a mitochondrial inherited disorder should be
suspected and appropriate diagnostic measures initiated.
Genetic testing should be guided by the phenotype, the
biopsy findings, and the biochemical results [60]. Mito-
chondrial encephalopathy, lactic acidosis and stroke-like
episodes (MELAS) and CoQ10 deficiency (primary or
secondary) would be important diagnostic consider-
ations. Sumatriptan has been described to be effective
in treatment of headaches associated with MELAS [61].
Pituitary apoplexy remains an important diagnostic con-
sideration for patients presenting with thunderclap headache
and should be considered a neuroendocrine emergency.
Apoplexy can occur in association with pregnancy, gen-
eral anesthesia, bromocriptine therapy, and pituitary ir-
radiation, but most commonly occurs in patients with no
known history of a pituitary tumor. Clinical symptoms
range from relatively mild symptoms including acute
headache, nausea to loss of vision, diplopia, and reduc-
tion in visual fields to adrenal crisis, coma, and sudden
death. Paucity of objective findings including normal
physical examinations, CT scans, and cerebrospinal fluid
have also been reported. MRI is the preferred imaging
modality for correct diagnosis [62••].
Conclusion
Secondary vascular headaches represent a group of diverse
disorders that range from hyperacute to subacute in presen-
tation, with a progressive course. They may be easily missed
and mistaken for a primary headache disorder. Prompt
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recognition and early treatment is essential to avoid some
preventable complications. Treatment recommendations are
generally controversial, based on tradition and lack evidence
of benefit or clear superiority of one treatment. Future research
will be essential to address the many unanswered questions.
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